WELCOME 2017-11-20T20:36:25+00:00

Bexion Pharmaceuticals, Inc. Presentations Accepted at 2018 ASCO Annual Meeting

April 16th, 2018|0 Comments

FOR IMMEDIATE RELEASE Covington, KY April 16, 2018 - Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain tumors, announced today that the four abstracts submitted for presentation at the American Society of Clinical [...]

Q2 – 2018 Newsletter

April 9th, 2018|0 Comments

Dear Friends of Bexion EXCITING NEWS! PHASE I CLINICAL TRIAL UPDATE The Phase Ia rising dose portion of the Phase I BXQ-350 trial has shown preliminary clinical activity in adult patients who had previously been [...]

Bexion Pharmaceuticals, Inc. to Present at the 25th Annual Meeting of Future Leaders in the BioTech Industry

February 14th, 2018|0 Comments

FOR IMMEDIATE RELEASE Covington, KY ~ February 14, 2018 - Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that Dr. Ray Takigiku, Founder and CEO of the Company [...]

Bexion Pharmaceuticals is developing innovative cures for cancer.

Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.

Read More About Bexion
Clinical Trials

Clinical Trials

In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).

Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857